Index
1 Market Overview of Mild-to-Moderate Atopic Dermatitis Treatment
1.1 Mild-to-Moderate Atopic Dermatitis Treatment Market Overview
1.1.1 Mild-to-Moderate Atopic Dermatitis Treatment Product Scope
1.1.2 Mild-to-Moderate Atopic Dermatitis Treatment Market Status and Outlook
1.2 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Region (2018-2029)
1.4 Global Mild-to-Moderate Atopic Dermatitis Treatment Historic Market Size by Region (2018-2023)
1.5 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Mild-to-Moderate Atopic Dermatitis Treatment Market Size (2018-2029)
1.6.1 North America Mild-to-Moderate Atopic Dermatitis Treatment Market Size (2018-2029)
1.6.2 Europe Mild-to-Moderate Atopic Dermatitis Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Mild-to-Moderate Atopic Dermatitis Treatment Market Size (2018-2029)
1.6.4 Latin America Mild-to-Moderate Atopic Dermatitis Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Mild-to-Moderate Atopic Dermatitis Treatment Market Size (2018-2029)
2 Mild-to-Moderate Atopic Dermatitis Treatment Market by Type
2.1 Introduction
2.1.1 Radiation Treatment
2.1.2 Drug Treatment
2.2 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Mild-to-Moderate Atopic Dermatitis Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Mild-to-Moderate Atopic Dermatitis Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Type (2018-2029)
3 Mild-to-Moderate Atopic Dermatitis Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Mild-to-Moderate Atopic Dermatitis Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Mild-to-Moderate Atopic Dermatitis Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Mild-to-Moderate Atopic Dermatitis Treatment Revenue Breakdown by Application (2018-2029)
4 Mild-to-Moderate Atopic Dermatitis Treatment Competition Analysis by Players
4.1 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mild-to-Moderate Atopic Dermatitis Treatment as of 2022)
4.3 Date of Key Players Enter into Mild-to-Moderate Atopic Dermatitis Treatment Market
4.4 Global Top Players Mild-to-Moderate Atopic Dermatitis Treatment Headquarters and Area Served
4.5 Key Players Mild-to-Moderate Atopic Dermatitis Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Mild-to-Moderate Atopic Dermatitis Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.1.4 Novartis Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.2.4 Pfizer Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Sanofi
5.3.1 Sanofi Profile
5.3.2 Sanofi Main Business
5.3.3 Sanofi Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.3.4 Sanofi Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Anacor Pharmaceuticals Recent Developments
5.4 Anacor Pharmaceuticals
5.4.1 Anacor Pharmaceuticals Profile
5.4.2 Anacor Pharmaceuticals Main Business
5.4.3 Anacor Pharmaceuticals Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.4.4 Anacor Pharmaceuticals Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Anacor Pharmaceuticals Recent Developments
5.5 Astellas Pharma
5.5.1 Astellas Pharma Profile
5.5.2 Astellas Pharma Main Business
5.5.3 Astellas Pharma Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.5.4 Astellas Pharma Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Astellas Pharma Recent Developments
5.6 Meda Pharmaceuticals
5.6.1 Meda Pharmaceuticals Profile
5.6.2 Meda Pharmaceuticals Main Business
5.6.3 Meda Pharmaceuticals Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.6.4 Meda Pharmaceuticals Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Meda Pharmaceuticals Recent Developments
5.7 Regeneron Pharmaceuticals
5.7.1 Regeneron Pharmaceuticals Profile
5.7.2 Regeneron Pharmaceuticals Main Business
5.7.3 Regeneron Pharmaceuticals Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.7.4 Regeneron Pharmaceuticals Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Regeneron Pharmaceuticals Recent Developments
5.8 Bausch Health
5.8.1 Bausch Health Profile
5.8.2 Bausch Health Main Business
5.8.3 Bausch Health Mild-to-Moderate Atopic Dermatitis Treatment Products, Services and Solutions
5.8.4 Bausch Health Mild-to-Moderate Atopic Dermatitis Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Bausch Health Recent Developments
6 North America
6.1 North America Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Mild-to-Moderate Atopic Dermatitis Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Mild-to-Moderate Atopic Dermatitis Treatment Market Dynamics
11.1 Mild-to-Moderate Atopic Dermatitis Treatment Industry Trends
11.2 Mild-to-Moderate Atopic Dermatitis Treatment Market Drivers
11.3 Mild-to-Moderate Atopic Dermatitis Treatment Market Challenges
11.4 Mild-to-Moderate Atopic Dermatitis Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List